相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists
Wouter Bulten et al.
MODERN PATHOLOGY (2021)
AI-based pathology predicts origins for cancers of unknown primary
Ming Y. Lu et al.
NATURE (2021)
Deep learning for diagnosis and survival prediction in soft tissue sarcoma
S. Foersch et al.
ANNALS OF ONCOLOGY (2021)
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
Boju Pan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
Xinran Wang et al.
NPJ BREAST CANCER (2021)
Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
Jingxin Liu et al.
SCIENTIFIC REPORTS (2021)
A Prospective Validation and Observer Performance Study of a Deep Learning Algorithm for Pathologic Diagnosis of Gastric Tumors in Endoscopic Biopsies
Jeonghyuk Park et al.
CLINICAL CANCER RESEARCH (2021)
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
Moritz Widmaier et al.
MODERN PATHOLOGY (2020)
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation
Han-Na Kim et al.
VIRCHOWS ARCHIV (2020)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
K. Park et al.
ANNALS OF ONCOLOGY (2020)
Artificial intelligence as the next step towards precision pathology
B. Acs et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
Ole-Johan Skrede et al.
LANCET (2020)
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
Fabio Pagni et al.
CANCERS (2020)
On the Interpretability of Artificial Intelligence in Radiology: Challenges and Opportunities
Mauricio Reyes et al.
RADIOLOGY-ARTIFICIAL INTELLIGENCE (2020)
Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities
Matthew P. Humphries et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Digital pathology and artificial intelligence
Muhammad Khalid Khan Niazi et al.
LANCET ONCOLOGY (2019)
The practical implementation of artificial intelligence technologies in medicine
Jianxing He et al.
NATURE MEDICINE (2019)
High-performance medicine: the convergence of human and artificial intelligence
Eric J. Topol
NATURE MEDICINE (2019)
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer
Clive R. Taylor et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
Sunhee Chang et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma
Viktor H. Koelzer et al.
HISTOPATHOLOGY (2018)
Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer
David F. Steiner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies
Ansh Kapil et al.
SCIENTIFIC REPORTS (2018)
Faster R-CNN: Towards Real-Time Object Detection with Region Proposal Networks
Shaoqing Ren et al.
IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE (2017)
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
Pedro N. Aguiar et al.
IMMUNOTHERAPY (2017)
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
Hans Brunnstrom et al.
MODERN PATHOLOGY (2017)
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer
Wendy A. Cooper et al.
CLINICAL CANCER RESEARCH (2017)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
